2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in 2024 and beyond.

| More on:
Cannabis stocks have fallen.

Canadian investors looking to gain exposure to marijuana stocks should look at companies south of the border. While quality U.S. marijuana stocks are close to generating consistent profits and cash flows, domestic cannabis producers continue to wrestle with industry-wide headwinds ranging from tepid demand, high inventory levels, oversupply, and mounting losses.

The U.S. is the world’s largest marijuana market, and the country may legalize the recreational consumption of pot at the federal level. This move should allow U.S.-based marijuana producers access to traditional sources of finance and the possibility to gain traction in other markets.

Keeping these factors in mind, the two best marijuana stocks you can buy this month include Green Thumb Industries (CNSX:GTII) and Curaleaf (TSX:CURA). Let’s see why.

The bull case for Green Thumb Industries stock

Valued at US$3.3 billion by market cap, Green Thumb Industries has trailed the broader markets in the last five years, falling over 6% in this period. Today, the cannabis stock trades 62% below all-time highs, allowing you to buy the dip.

While most of its peers are struggling with consistent losses, Green Thumb has reported a GAAP (generally accepted accounting principles) profit for three consecutive quarters. In the quarter ended in September, it reported revenue of $275.4 million and a net income of $10.5 million.

With 90 retail stores, Green Thumb reaches half the country’s population and remains a top investment choice for long-term shareholders.

Green Thumb reported an adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) of US$83 million in the third quarter (Q3), indicating a healthy margin of 30%. In the first three quarters of 2023, its operating cash flow stood at US$154 million, and the company ended the period with a cash balance of US$137 million.

Green Thumb continues to focus on operational efficiency, working capital management, and cash flow generation while navigating a sluggish macro environment in 2024. Moreover, Green Thumb is positioned to expand its adjusted earnings from US$0.05 per share in 2022 to US$0.24 per share in 2024.

The bull case for Curaleaf stock

Valued at a market cap of US$3.76 billion, Curaleaf reported revenue of US$333 million with an EBITDA margin of 23% in Q3. It reduced inventory by US$18 million, allowing it to end Q3 with a free cash flow of US$33 million and a cash balance of US$118 million.

Curaleaf International is a subsidiary of Curaleaf Holdings and is the largest vertically integrated cannabis company in Europe. Recently, Curaleaf International announced the acquisition of Can4Med, a Poland-based wholesaler operating in the medical marijuana segment.

Poland has one of the largest patient populations seeking medical cannabis in Europe, and the acquisition provides Curaleaf with a strong foothold in a high-growth market.

According to Matt Darin, the chief executive officer of Curaleaf, “This acquisition represents a significant step forward for Curaleaf International. Poland’s medical cannabis market is expanding rapidly, and our partnership with Can4Med allows us to better serve patients while driving growth across Europe.”

While Curaleaf is unprofitable, it should narrow its losses from $0.52 per share in 2022 to $0.13 per share in 2024.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool recommends Green Thumb Industries. The Motley Fool has a disclosure policy.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »